Advertisement
News
Subscribe to MDT Magazine News

Reportlinker Adds Advances in SPECT Imaging (Technical Insights)

March 9, 2011 7:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 9, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Advances in SPECT Imaging (Technical Insights) http://www.reportlinker.com/p0443053/Advances-in-SPECT-Imaging-Technical-Insights.html This research service evaluates the...

TOPICS:

University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System

March 9, 2011 7:33 am | by Bio-Medicine.Org | Comments

CLEVELAND, March 9, 2011 /- The University of Wisconsin Carbone Cancer Center (UWCCC) in Madison, Wisconsin, will soon become one of the first oncology research centers to acquire a radiotherapy system from ViewRay™, Inc., a privately held medical device company. ViewRay's new...

TOPICS:

Consumer Information on: Selenia Dimensions 3D System - P080003

March 9, 2011 6:36 am | by U.S. Food & Drug Administration | Comments

The Selenia Dimensions 3D System is comprised of hardware and software upgrades to the Selenia Dimensions 2D full-field digital mammography system, which is FDA approved for conventional mammography. The hardware upgrades produces multiple, low-dose x-ray

Advertisement

Summary Information for: Selenia Dimensions 3D System

March 9, 2011 6:36 am | by U.S. Food & Drug Administration | Comments

Labeling, Approval Order, and Summary of Safety and Effectiveness for Selenia Dimensions 3D System (P080003).

Hospira Announces U.S. Approval of Generic Docetaxel

March 9, 2011 6:34 am | by Bio-Medicine.Org | Comments

LAKE FOREST, Ill., March 9, 2011 /- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of docetaxel. The medication is a generic version of Sanofi-Aventis's Taxotere®, and Hospira...

TOPICS:

Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism

March 9, 2011 6:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 9, 2011 /- As part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, the Coalition to Prevent DVT is focusing on the importance of DVT and its risk factors among patients with co-morbid conditions – including but not limited to cancer, heart or...

TOPICS:

Endo to Present at the Barclays Capital 2011 GlobalHealthcare Conference

March 9, 2011 6:34 am | by Bio-Medicine.Org | Comments

CHADDS FORD, Pa., March 9, 2011  /- Endo Pharmaceuticals (Nasdaq: ENDP ) today announced that it will present at the Barclays Capital 2011 GlobalHealthcare Conference on Tuesday, March 15, 2011 at 3:45 p.m. ET.  Dr. Ivan Gergel executive vice president of R&D of Endo will...

TOPICS:

Md. delays action on $2.4B prescription drug deal

March 9, 2011 5:45 am | by BRIAN WITTE - Associated Press - Associated Press | Comments

A $2.4 billion contract for a prescription drug plan for Maryland state employees has been pulled from a state board's Wednesday agenda after a company competing for the contract filed its fourth protest about the procurement process.Sheila McDonald, the executive secretary of the Board of...

Advertisement

Medtronic resolves FDA warnings over 2 factories

March 9, 2011 5:45 am | by The Associated Press | Comments

Medtronic Inc., the world's largest medical device company, says it has resolved two warning letters from the Food and Drug Administration over lax oversight at two manufacturing plants, clearing the way for new product approvals.The FDA cited the company in November 2009 and June 2009 over...

Stonewedge still stealthy after second $1M round

March 9, 2011 4:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Andover startup Stonewedge Corp. has taken in $1 million from a single, unnamed investor, bringing to $2 million the amount the stealthy wellness technology company has raised.

Contrast Media Reactions Are Allergic, but Minor

March 9, 2011 4:34 am | by Diagnostic Imaging | Comments

Final results of the prospective French CIRTACI trial are in: contrast media for diagnostic imaging are very safe in general, as long as radiologists are vigilant for patients with allergies, asthma, or previous reactions to contrast agents. The vast majority are more itchy than serious.

TOPICS:

Improving on PET: Adding a Blue Glow, Removing a Crystal

March 9, 2011 4:34 am | by Diagnostic Imaging | Comments

PET hybrid technologies are already hot, and two innovations discussed during the final session of ECR 2011 are aimed at making them more even powerful and efficient.

TOPICS:

Photo Release -- PositiveID Corporation Completes Development of Its iglucose(TM) Mobile Health Solution for Real-Time Diabetes Management

March 9, 2011 4:34 am | by PositiveID | Comments

Photo Release -- PositiveID Corporation Completes Development of Its iglucose(TM) Mobile Health Solution for Real-Time Diabetes Management

TOPICS:

Walgreen selling pharmacy benefits ops for $525M

March 9, 2011 3:45 am | by The Associated Press | Comments

Walgreen Cos. says it will sell its pharmacy benefits management business to Catalyst Health Solutions Inc. for $525 million in cash.Walgreen says it is focusing on its drugstore network, which is the largest in the U.S., along with its specialty pharmacy and mail service businesses.The...

Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronie's Disease

March 9, 2011 3:35 am | by Bio-Medicine.Org | Comments

MALVERN, Pa., March 9, 2011 /- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty biopharmaceutical company, today announced it has reached the target enrollment for the double-blind placebo-controlled phase III program of XIAFLEX ® for the treatment of Peyronie's disease....

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading